SLU-PP-915

SLU-PP-915 is a synthetic, orally bioavailable pan-agonist of the estrogen-related receptors developed as a chemically distinct successor to the prototype exercise mimetic SLU-PP-332 ^[1]. Like its predecessor it activates the ERR family of orphan nuclear receptors that govern mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and the Krebs cycle, and it is classified in the literature as an exercise-mimetic ERR agonist ^[1][2].

The defining advance of SLU-PP-915 is pharmacokinetic. The original SLU-PP-332 improved aerobic performance in mice but lacked oral bioavailability, whereas SLU-PP-915 was characterized specifically as an orally active compound that retains potent in vivo exercise-mimetic activity ^[1]. In its primary report it enhanced aerobic exercise performance, measured as running distance and duration, to a degree similar to SLU-PP-332 when given by injection, and it maintained comparable efficacy when given orally after adjusting for systemic exposure ^[1]. It also robustly induced the acute-exercise gene Ddit4 and synergized with exercise training to further raise mitochondrial gene expression ^[1].

SLU-PP-915 is an investigational research compound without regulatory approval or human clinical use, and it is neither a supplement nor an approved medicine ^[1][2]. It is positioned as a valuable chemical tool for exploring the chronic therapeutic potential of ERR activation in metabolic disease, cardiovascular disease, and muscle-related conditions such as sarcopenia and muscular dystrophy ^[1][2]. Because ERR agonists reproduce exercise-like physiology, the compound is also of interest to anti-doping science, and analytical methods characterizing SLU-PP-915 and its metabolites have already been published, flagging it as off limits for tested athletes ^[3].

Honestly, the biggest safety fact is how little is known; SLU-PP-915 is entirely preclinical, with no human safety data of any kind and every finding coming from mice and cells. ERRs are expressed all over the body, including heart, skeletal muscle, brain, kidney, and brown fat, so a systemic pan-agonist can act far beyond the muscles you are trying to train, and the consequences of chronically forcing this pathway are simply not characterized in people. Cardiac energy metabolism and long-term heart remodeling are a particular unknown, which is notable given that ERR activation reshapes how the heart uses fuel.

The material is sold online as a research chemical not for human consumption, so purity, dose accuracy, and contamination are unverified. There is no established human dose, no mapped drug interactions, and no reversal agent. Anti-doping scientists have already flagged it as an exercise mimetic with doping potential and worked out detection methods, so any athlete under WADA-style testing should assume it is prohibited and traceable. The short version; genuinely interesting science, but taking it yourself is an unknown-risk gamble.

SLU-PP-915 came out of the laboratory of Thomas P. Burris, whose group at Saint Louis University and later the University of Florida developed a series of estrogen-related receptor (ERR) agonists as candidate exercise mimetics. It was designed as a second-generation analog of the earlier ERR agonist SLU-PP-332, built around a phenylboronic acid pharmacophore to improve metabolic stability and oral bioavailability while retaining pan-ERR potency. Published rodent work showed that orally dosed SLU-PP-915 raised aerobic exercise capacity comparably to injected SLU-PP-332, alongside effects on energy expenditure and fatty-acid oxidation. The compound is covered by Saint Louis University intellectual property but remains a preclinical research chemical with no FDA approval and no published human trials, and it circulates largely through the research-chemical grey market.